SSKN · Strata Skin Sciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $6.93M | $7.66M | $6.81M | - | $8.80M | $8.44M | $6.75M | - | $8.85M |
| Cost of Revenue | - | $2.75M | $3.36M | $3.17M | - | $3.49M | $3.50M | $3.67M | - | $3.90M |
| Gross Profit | - | $4.18M | $4.31M | $3.65M | - | $5.31M | $4.94M | $3.08M | - | $4.95M |
| R&D | - | $172.0K | $86.0K | $96.0K | - | $243.0K | $199.0K | $241.0K | - | $248.0K |
| SG&A | - | $2.67M | $2.91M | $2.57M | - | $3.67M | $2.21M | $2.71M | - | $2.28M |
| Total Operating Expenses | - | $5.36M | $6.53M | $5.66M | - | $6.96M | $5.42M | $5.97M | - | $5.57M |
| D&A | - | $864.0K | $1.22M | $1.22M | - | $1.24M | $1.25M | $1.25M | - | $1.45M |
| Operating Income | - | ($1.17M) | ($2.22M) | ($2.02M) | - | ($1.65M) | ($486.0K) | ($2.89M) | - | ($615.0K) |
| Interest Expense | - | $498.0K | $491.0K | $524.0K | - | $537.0K | $298.0K | $524.0K | - | $528.0K |
| Income Tax | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - | $0 |
| Net Income | - | ($1.62M) | ($2.49M) | ($2.43M) | - | ($2.12M) | ($99.0K) | ($3.37M) | - | ($1.05M) |
| EPS - Basic | - | ($0.36) | ($0.60) | ($0.58) | - | ($0.53) | ($0.03) | ($1.00) | - | ($0.30) |
| EPS - Diluted | - | ($0.36) | ($0.60) | ($0.58) | - | ($0.53) | ($0.03) | ($1.00) | - | ($0.30) |
Balance Sheet
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.91M | $7.08M | $5.97M | $6.51M | $7.26M | $7.06M | $5.48M | $5.24M | $6.78M | $7.13M |
| Accounts Receivable | $4.12M | $3.50M | $4.02M | $5.01M | $5.25M | $4.44M | $3.98M | $3.63M | $4.44M | $4.80M |
| Inventory | $2.81M | $3.06M | $3.24M | $2.66M | $2.25M | $2.74M | $2.69M | $2.69M | $2.67M | $6.13M |
| Accounts Payable | $2.76M | $2.96M | $2.94M | $2.82M | $2.43M | $1.75M | $2.89M | $3.59M | $3.34M | $3.16M |
| Current Assets | $15.60M | $14.27M | $13.77M | $15.88M | $16.59M | $15.88M | $13.82M | $13.24M | $15.54M | $19.72M |
| Total Assets | $30.52M | $30.72M | $30.72M | $34.26M | $36.16M | $40.20M | $39.58M | $40.05M | $42.02M | $47.19M |
| Current Liabilities | $26.74M | $15.03M | $14.00M | $15.14M | $14.63M | $14.05M | $12.13M | $12.59M | $12.17M | $12.03M |
| Long-term Debt | $0 | $13.44M | $15.27M | $15.23M | $15.19M | $15.15M | $15.11M | $15.07M | $15.04M | $15.02M |
| Total Liabilities | $27.61M | $29.40M | $30.41M | $31.59M | $31.18M | $30.86M | $30.09M | $30.62M | $29.33M | $31.00M |
| Stockholders' Equity | $2.91M | $1.31M | $308.0K | $2.67M | $4.97M | $9.34M | $9.50M | $9.43M | $12.69M | $16.19M |
| Retained Earnings | ($254.41M) | ($254.46M) | ($253.06M) | ($250.58M) | ($248.14M) | ($243.65M) | ($241.53M) | ($241.43M) | ($238.06M) | ($234.26M) |
Cash Flow
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($550.0K) | - | - | - | ($804.0K) | - | - |
| Investing Cash Flow | - | - | - | ($199.0K) | - | - | - | ($725.0K) | - | - |
| Financing Cash Flow | - | - | - | $0 | - | - | - | ($18.0K) | - | - |
| CapEx | - | - | - | $199.0K | - | - | - | $725.0K | - | - |
| Free Cash Flow | - | - | - | ($749.0K) | - | - | - | ($1.53M) | - | - |
Ratios
| Metric | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | 60.4% | 56.2% | 53.5% | - | 60.3% | 58.5% | 45.6% | - | 56.0% |
| Operating margin | - | -16.9% | -29.0% | -29.6% | - | -18.8% | -5.8% | -42.8% | - | -6.9% |
| EBITDA margin | - | -4.5% | -13.1% | -11.7% | - | -4.7% | 9.1% | -24.3% | - | 9.4% |
| Net margin | - | -23.4% | -32.5% | -35.7% | - | -24.1% | -1.2% | -49.9% | - | -11.9% |
| Free cash flow margin | - | - | - | -11.0% | - | - | - | -22.6% | - | - |
| FCF / Net income | - | - | - | 0.31 | - | - | - | 0.45 | - | - |
| R&D / Revenue | - | 2.5% | 1.1% | 1.4% | - | 2.8% | 2.4% | 3.6% | - | 2.8% |
| SG&A / Revenue | - | 38.5% | 38.0% | 37.8% | - | 41.7% | 26.2% | 40.1% | - | 25.8% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -5.3% | -8.1% | -7.1% | - | -5.3% | -0.3% | -8.4% | - | -2.2% |
| Return on equity | - | -123.4% | -808.1% | -91.1% | - | -22.7% | -1.0% | -35.7% | - | -6.5% |
| Return on invested capital | - | -6.3% | -11.3% | -8.9% | - | -5.3% | -1.6% | -9.3% | - | -1.6% |
| Liquidity | ||||||||||
| Current ratio | 0.58 | 0.95 | 0.98 | 1.05 | 1.13 | 1.13 | 1.14 | 1.05 | 1.28 | 1.64 |
| Quick ratio | 0.48 | 0.75 | 0.75 | 0.87 | 0.98 | 0.94 | 0.92 | 0.84 | 1.06 | 1.13 |
| Cash ratio | 0.30 | 0.47 | 0.43 | 0.43 | 0.50 | 0.50 | 0.45 | 0.42 | 0.56 | 0.59 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | 10.22 | 49.58 | 5.71 | 3.06 | 1.62 | 1.59 | 1.60 | 1.19 | 0.93 |
| Debt / Assets | 0.00 | 0.44 | 0.50 | 0.44 | 0.42 | 0.38 | 0.38 | 0.38 | 0.36 | 0.32 |
| Debt / EBITDA | - | - | - | - | - | - | 19.78 | - | - | 18.00 |
| Interest coverage | - | -2.4x | -4.5x | -3.8x | - | -3.1x | -1.6x | -5.5x | - | -1.2x |
| Equity multiplier | 10.50 | 23.38 | 99.75 | 12.84 | 7.27 | 4.30 | 4.17 | 4.25 | 3.31 | 2.91 |
| Liabilities / Assets | 0.90 | 0.96 | 0.99 | 0.92 | 0.86 | 0.77 | 0.76 | 0.76 | 0.70 | 0.66 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.23 | 0.25 | 0.20 | - | 0.22 | 0.21 | 0.17 | - | 0.19 |
| Inventory turnover | - | 0.90 | 1.04 | 1.19 | - | 1.27 | 1.30 | 1.36 | - | 0.64 |
| Days sales outstanding | - | 185d | 192d | 268d | - | 184d | 172d | 196d | - | 198d |
| Days inventory outstanding | - | 407d | 352d | 307d | - | 287d | 281d | 268d | - | 574d |
| Days payable outstanding | - | 393d | 320d | 325d | - | 183d | 301d | 357d | - | 296d |
| Cash conversion cycle | - | 198d | 223d | 250d | - | 288d | 152d | 107d | - | 476d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | 7.0x | 31.0x | 4.1x | - | 1.2x | 1.1x | 14.1x | - | 12.9x |
| P / S | - | 1.3x | 1.2x | 1.6x | - | 1.3x | 1.3x | 19.7x | - | 23.7x |
| EV / EBITDA | - | - | - | - | - | - | 26.7x | - | - | 260.6x |
| Growth | ||||||||||
| Revenue growth (YoY) | - | -21.2% | -9.2% | 0.9% | - | -0.6% | 2.2% | -10.7% | - | -6.0% |
| Revenue CAGR (3y) | - | -9.7% | -5.6% | -1.1% | - | 4.5% | 4.5% | 5.0% | - | 16.4% |
| Revenue CAGR (5y) | - | 4.3% | 13.7% | 0.2% | - | 3.3% | 1.8% | -2.0% | - | 4.0% |
| Gross profit growth (YoY) | - | -21.2% | -12.8% | 18.4% | - | 7.1% | 14.3% | -29.8% | - | -14.6% |
| Operating income growth (YoY) | - | 29.0% | -357.6% | 30.3% | - | -168.8% | 75.2% | -11.7% | - | 21.8% |
| Net income growth (YoY) | - | 23.6% | -2414.1% | 27.8% | - | -101.5% | 96.9% | -18.8% | - | -5.8% |
| EPS growth (YoY) | - | 32.1% | -1900.0% | 42.0% | - | -76.7% | 66.7% | -1150.0% | - | -1400.0% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | 51.0% | - | - | - | 41.4% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -41.5% | -85.9% | -96.8% | -71.7% | -60.8% | -42.3% | -43.8% | -51.2% | -41.9% | -25.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$30.70M totalDermatology Recurring Procedures$21.48M · 70.0%
Dermatology Procedures Equipment$9.22M · 30.0%
Geographic
$26.73M totalUS$19.57M · 73.2%
CN$3.35M · 12.6%
Geographic Distribution Other Foreign$1.91M · 7.1%
Middle East$1.90M · 7.1%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing STRATA Skin Sciences against the 5 most active filers in the same SIC group.